Cancer Family
Childhood Neoplasm
CI-CAN-00000009Explore in graph →
PediatricNon-malignant312 active trials1 approved drugs68 evidence items
- NCIt
- C6283
Loading cancer entity…
Cancer Family
CI-CAN-00000009Explore in graph →
Clinical trials
1,503 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | not yet recruiting | Phase 1 / Phase 2 | 79 | Children's Oncology GroupNETWORK | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | not yet recruiting | Phase 1 / Phase 2 | 77 | Children's Oncology GroupNETWORK | 0 | Sep 15, 2026 |
| clinicaltrials |
| NCT07773454 | Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 18 | ExelixisINDUSTRY | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials